JP2022543062A5 - - Google Patents

Info

Publication number
JP2022543062A5
JP2022543062A5 JP2022506474A JP2022506474A JP2022543062A5 JP 2022543062 A5 JP2022543062 A5 JP 2022543062A5 JP 2022506474 A JP2022506474 A JP 2022506474A JP 2022506474 A JP2022506474 A JP 2022506474A JP 2022543062 A5 JP2022543062 A5 JP 2022543062A5
Authority
JP
Japan
Prior art keywords
cancer
combination pharmaceutical
combination
pharmaceutical according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543062A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044533 external-priority patent/WO2021022172A1/en
Publication of JP2022543062A publication Critical patent/JP2022543062A/ja
Publication of JP2022543062A5 publication Critical patent/JP2022543062A5/ja
Pending legal-status Critical Current

Links

JP2022506474A 2019-08-01 2020-07-31 Ido阻害剤の投与レジメン Pending JP2022543062A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881518P 2019-08-01 2019-08-01
US62/881,518 2019-08-01
PCT/US2020/044533 WO2021022172A1 (en) 2019-08-01 2020-07-31 A dosing regimen for an ido inhibitor

Publications (2)

Publication Number Publication Date
JP2022543062A JP2022543062A (ja) 2022-10-07
JP2022543062A5 true JP2022543062A5 (cg-RX-API-DMAC7.html) 2024-03-18

Family

ID=72139706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506474A Pending JP2022543062A (ja) 2019-08-01 2020-07-31 Ido阻害剤の投与レジメン

Country Status (11)

Country Link
US (1) US20210030869A1 (cg-RX-API-DMAC7.html)
EP (1) EP4007602A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022543062A (cg-RX-API-DMAC7.html)
KR (1) KR20220044527A (cg-RX-API-DMAC7.html)
CN (1) CN114502196A (cg-RX-API-DMAC7.html)
AU (1) AU2020319875A1 (cg-RX-API-DMAC7.html)
CA (1) CA3148776A1 (cg-RX-API-DMAC7.html)
IL (1) IL290006A (cg-RX-API-DMAC7.html)
MX (1) MX2022001133A (cg-RX-API-DMAC7.html)
PH (1) PH12022550246A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021022172A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
US12122848B2 (en) * 2020-07-09 2024-10-22 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Compositions and methods for treating fibroids
JP2024502005A (ja) * 2020-12-29 2024-01-17 インサイト・コーポレイション A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法
CA3224640A1 (en) 2021-07-09 2023-01-12 Krishnan SAMPATHKUMAR Pharmaceutical compositions of a pd-1 antibody and use of the same
KR20240042109A (ko) * 2021-08-13 2024-04-01 어젠시스 인코포레이티드 191P4D12 단백질에 결합하는 항체 약물 접합체[Antibody Drug Conjugate, ADC]로 비근침윤성 방광암[Non-muscle invasive bladder cancer, NMIBC]을 치료하는 방법
WO2026026944A1 (zh) * 2024-08-02 2026-02-05 应世生物科技(南京)有限公司 新用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
EP3744715A1 (en) 2013-11-08 2020-12-02 Incyte Holdings Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN108472245A (zh) * 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
AU2019205904A1 (en) * 2018-01-05 2020-06-18 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy

Similar Documents

Publication Publication Date Title
CN109963592B (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP2021513540A5 (cg-RX-API-DMAC7.html)
JP2019519499A5 (cg-RX-API-DMAC7.html)
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2017514795A5 (cg-RX-API-DMAC7.html)
JP2023516441A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2021511372A5 (cg-RX-API-DMAC7.html)
CN111132696A (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2023510199A5 (cg-RX-API-DMAC7.html)
JP2023515675A5 (cg-RX-API-DMAC7.html)
JP2019524714A5 (cg-RX-API-DMAC7.html)
JP2019532970A5 (cg-RX-API-DMAC7.html)
US12053530B2 (en) Plectin-1 binding antibodies and uses thereof
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
CN120437288A (zh) 治疗卵巢癌的药物组合
JP2023500480A5 (cg-RX-API-DMAC7.html)
JP2024521105A5 (cg-RX-API-DMAC7.html)
CN115698076A (zh) 用于治疗肿瘤的药物
JP2022547061A5 (cg-RX-API-DMAC7.html)
JP2023531090A5 (cg-RX-API-DMAC7.html)
CN120437318A (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
JP2022549218A5 (cg-RX-API-DMAC7.html)
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合